Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Hexima Limited
  6. News
  7. Summary
    HXL   AU0000111932

HEXIMA LIMITED

(HXL)
SummaryChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Jake Nunn Joins Board of Hexima Limited as Non-Executive Director, effective 1 September 2021

08/31/2021 | 07:33pm EDT

Hexima Limited announced that Mr. Jake Nunn will join its board as a Non-Executive Director, effective 1 September 2021. Mr. Nunn has more than 25 years' experience in the life science industry as an investor, independent director, research analyst and investment banker. Jake is currently an independent advisor to several life science companies and a venture advisor at New Enterprise Associates (NEA), where he was an investing partner from 2006 to 2018 focused on the biopharmaceutical and medical technology sectors. Mr. Nunn is a director of public companies Regulus Therapeutics Inc, Oventus Medical Ltd, Trevena Inc, and Addex Therapeutics Ltd. He was previously a director of several companies in the pharmaceutical sector including Dermira Inc. (acquired by Eli Lilly) and Hyperion Therapeutics (acquired by Horizon Pharma plc).


ę S&P Capital IQ 2021
All news about HEXIMA LIMITED
10/05Hexima Limited Announces Company Secretary Change
CI
09/253,559,437 Ordinary Shares of Hexima Limited are subject to a Lock-Up Agreement Ending o..
CI
08/31Jake Nunn Joins Board of Hexima Limited as Non-Executive Director, effective 1 Septembe..
CI
08/27HEXIMA : 2021áAnnual Financial Report
PU
08/27Hexima Limited Reports Earnings Results for the Full Year Ended June 30, 2021
CI
08/27Hexima Limited Auditor Raises 'Going Concern' Doubt
CI
08/24HEXIMA : Secures Chinese Patent for Fungal Nail Infection Treatment; Shares Surge 12%
MT
08/18Hexima Limited Announces Design Patent for Pezadeftide Commercial Packaging
CI
07/25Hexima Limited Announces Completion of Enrolment in Phase IIb Clinical Trial
CI
07/13HEXIMA : Expects to Secure European Patent for Nail Fungal Infection Treatment
MT
More news
Financials
Sales 2021 4,08 M 3,06 M 3,06 M
Net income 2021 -6,87 M -5,15 M -5,15 M
Net cash 2021 3,39 M 2,54 M 2,54 M
P/E ratio 2021 -2,77x
Yield 2021 -
Capitalization 49,7 M 37,2 M 37,3 M
EV / Sales 2020 -
EV / Sales 2021 4,62x
Nbr of Employees -
Free-Float 38,3%
Chart HEXIMA LIMITED
Duration : Period :
Hexima Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
Michael Douglas Arthur Aldridge CEO, Non-Independent Non-Executive Director & MD
Jonathan West Non-Executive Chairman
Marilyn Ann Anderson Executive Director & Chief Scientific Officer
Yolanda Gaspar Head-Clinical Operations
Nicole Louise van der Weerden Chief Operating Officer & Executive Director
Sector and Competitors
1st jan.Capi. (M$)
HEXIMA LIMITED105.41%37
MODERNA, INC.212.57%131 807
LONZA GROUP AG32.74%61 177
IQVIA HOLDINGS INC.43.38%49 076
SEAGEN INC.-2.12%31 189
CELLTRION, INC.-38.86%25 455